Drug updated on 12/11/2024
| Dosage Form | Injection (intravenous; 1 mg/mL, 30 mg/30 mL [1 mg/mL]) |
| Drug Class | Bispecific CD20-directed CD3 T-cell engagers |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Mosunetuzumab demonstrated superior complete response (CR) and objective response rate (ORR) compared to tazemetostat in Enhancer of Zeste Homolog 2 (EZH2) wild-type patients, as well as better CR and ORR compared to phosphatidylinositol 3-kinase (PI3K) inhibitors, while chimeric antigen receptor (CAR) T therapies had a slight advantage over mosunetuzumab in these measures.
- Mosunetuzumab showed better progression-free survival (PFS) compared to umbralisib, a PI3K inhibitor, but CAR T therapies were favored in terms of PFS.
- Fewer discontinuations due to adverse events were reported for mosunetuzumab compared to PI3K inhibitors.
- Mosunetuzumab had fewer discontinuations due to adverse events compared to PI3K inhibitors.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Lunsumio (mosunetuzumab-axgb) Prescribing Information. | 2022 | Genetech Inc., South San Francisco, CA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma | 2024 | Clinical Lymphoma, Myeloma & Leukemia |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023. | 2023 | Journal of the National Comprehensive Cancer Network |